SCM
ATYR

Sterling Capital Management’s aTyr Pharma ATYR Stock Holding History

Sterling Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-742
Closed -$579 – 3434
2026
Q1 		$579 Sell
742
-192
-21% -$162 ﹤0.01% 3143
2025
Q4 		$731 Buy
934
+331
+55% +$272 ﹤0.01% 3164
2025
Q3 		$435 Buy
603
+248
+70% +$1.12K ﹤0.01% 3168
2025
Q2 		$1.8K Buy
+355
New +$1.4K ﹤0.01% 2944

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sterling Capital Management's ATYR Position: Q2 2026 in Review

Sterling Capital Management sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 742 shares — an estimated $579 sold.

Sterling Capital Management first reported a position in ATYR in Q2 2025 and held it in 4 quarters. The position peaked at $1.8K in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Sterling Capital Management reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
  • Sterling Capital Management sold 742 aTyr Pharma shares in Q2 2026, an estimated $579.
  • Sterling Capital Management first reported a position in aTyr Pharma in Q2 2025 and held it in 4 quarters.
  • Sterling Capital Management's aTyr Pharma position peaked at $1.8K in Q2 2025.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.